Back to Authors

Tepper, Stewart J.

https://orcid.org/0000-0002-9879-6638

A5064341657 | I107672454

Mayo Clinic

Dartmouth College

Citations 44

Total Migraine Freedom for Breath Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder (AVP-825) vs 100 mg Oral Sumatriptan from the COMPASS Study of Acute Treatment of Migraine (P6.098)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.p6.098

Total Migraine Freedom for Breath Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder (AVP-825) vs 100 mg Oral Sumatriptan from the COMPASS Study of Acute Treatment of Migraine (I3.009)

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.i3.009

A Multicenter, Prospective, Single Arm, Open Label, Post-Market, Observational Study to evaluate the use of sTMS in reduction of Migraine Headache (ESPOUSE Study) (S52.004)

Neurology | December 7, 2023 | Volume: 88 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.88.16_supplement.s52.004

Risk of Hypertension in Erenumab-treated Patients With Migraine in Clinical Trials and in the Postmarketing Setting (2168)

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.2168

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO) (870)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.870

Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2 (617)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.617

Rimegepant 75 mg Provides Early and Sustained Relief of Migraine With a Single Dose: Results from 3 Phase 3 Clinical Trials (2366)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.2366

Benefit of Migraine Prevention with Erenumab in Patients Receiving Background Standard-of-care Acute Treatment (1381)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1381

Cardiovascular Safety of Erenumab in Patients with Migraine and Aura (1209)

Neurology | December 7, 2023 | Volume: 94 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.94.15_supplement.1209

Real-World Healthcare Costs and Resource Utilization Among Patients Treated With Erenumab in the United States: A Retrospective Claims Database Study (P16-7.003)

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.394